相关实验视频

Updated: Jan 14, 2026

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

调查白质超强度对渐进性上核性的纵向进展的影响

Maria Francesca Tepedino¹, Francesco Diana^2,3, Anna Rosa Avallone¹

¹Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry ''Scuola Medica Salernitana'', University of Salerno, Via Allende, Baronissi, Salerno, 84131, Italy.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|October 17, 2025

概括

白质超强度 (WMH) 不能预测进步超核麻 (PSP) 的整体疾病进展. 然而,叶WMH可能表明预后更差,这表明它在疾病进展中发挥了特定的作用.

科学领域:

神经学神经学
神经成像是一种神经成像.
神经退行发生神经退行.

背景情况:

白质超强度 (WMH) 在渐进性超核麻 (PSP) 中很常见,并与小血管疾病有关.
它们对PSP疾病进展的预后意义尚不清楚.

研究的目的:

为了研究基线白质超强度 (WMH) 与进展性超核麻 (PSP) 患者的临床进展之间的关联.

主要方法:

60名PSP患者接受了3次特斯拉MRI和神经评估,平均随访时间为48.6个月.
白质过强度 (WMH) 用与年龄相关的白质变化 (ARWMC) 尺度进行评估.
用Kaplan-Meier和Cox回归分析了疾病里程碑和死亡的时间,并对共变量进行了调整.

主要成果:

65%的PSP患者在基线时有WMH (ARWMC平均得分为4.7).
整体WMH负担并没有显著预测到里程碑或死亡的时间.
较高的叶WMH得分与达到里程碑和死亡率相关 (p<0.001).

结论:

基线WMH负担不是PSP整体临床进展的显著预测指标.
叶WMH可以作为PSP疾病进展的特定预后标志物.
需要进一步的高级成像研究来阐明WMH在PSP病变发生中的作用.

关键词:

里程碑事件里程碑事件渐进性的超核性.白质的超强度是白质的超强度.

更多相关视频

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse

3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse

Published on: May 19, 2015

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...